Copyright
©The Author(s) 2015.
World J Gastroenterol. Sep 14, 2015; 21(34): 9966-9973
Published online Sep 14, 2015. doi: 10.3748/wjg.v21.i34.9966
Published online Sep 14, 2015. doi: 10.3748/wjg.v21.i34.9966
Table 3 Treatment response to chemotherapy according to the pre-treatment lymphocyte to monocyte ratio/neutrophil to lymphocyte ratio
| Response | LMR | NLR | ||||
| High (n = 64) | Low (n = 38) | P value | High (n = 51) | Low (n = 51) | P value | |
| CR | 2 | 2 | 2 | 2 | ||
| PR | 20 | 9 | 12 | 17 | ||
| SD | 31 | 13 | 22 | 22 | ||
| PD | 11 | 14 | 15 | 10 | ||
| Objective response rate | 34.4% | 28.9% | 0.664 | 27.5% | 37.3% | 0.397 |
| Disease control rate | 82.8% | 63.2% | 0.033 | 70.6% | 80.4% | 0.357 |
- Citation: Shibutani M, Maeda K, Nagahara H, Ohtani H, Sakurai K, Yamazoe S, Kimura K, Toyokawa T, Amano R, Tanaka H, Muguruma K, Hirakawa K. Prognostic significance of the lymphocyte-to-monocyte ratio in patients with metastatic colorectal cancer. World J Gastroenterol 2015; 21(34): 9966-9973
- URL: https://www.wjgnet.com/1007-9327/full/v21/i34/9966.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i34.9966